Posted by admin on Jul 22nd, 2022

DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) had its price objective reduced by investment analysts at Morgan Stanley from $48.00 to $44.00 in a research note issued on Wednesday, Stock Target Advisor reports. The brokerage currently has an “overweight” rating on the medical instruments supplier’s stock. Morgan Stanley’s price objective would suggest a potential upside of 20.65% from the stock’s previous close.

Several other research analysts have also recently commented on the company. Barrington Research cut their price target on DENTSPLY SIRONA from $53.00 to $51.00 in a research note on Wednesday, May 11th. The Goldman Sachs Group cut their price target on DENTSPLY SIRONA from $59.00 to $47.00 and set a “neutral” rating on the stock in a research note on Thursday, April 21st. Robert W. Baird cut DENTSPLY SIRONA from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $67.00 to $48.00 in a research note on Tuesday, April 19th. HC Wainwright cut their price target on DENTSPLY SIRONA from $58.00 to $48.00 and set a “hold” rating on the stock in a research note on Friday, April 22nd. Finally, StockNews.com cut DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $48.11.

Shares of NASDAQ XRAY opened at $36.47 on Wednesday. DENTSPLY SIRONA has a 1-year low of $33.78 and a 1-year high of $66.98. The business has a 50-day moving average of $37.07 and a 200-day moving average of $45.43. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.45 and a quick ratio of 1.03. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of 21.58 and a beta of 0.94.

DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) last issued its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.02. DENTSPLY SIRONA had a return on equity of 11.63% and a net margin of 8.81%. The company had revenue of $9.67 billion during the quarter, compared to the consensus estimate of $982.05 million. During the same quarter in the prior year, the business earned $0.72 earnings per share. The company’s revenue was up 841.1% compared to the same quarter last year. On average, equities analysts anticipate that DENTSPLY SIRONA will post 2.42 EPS for the current fiscal year.

In other DENTSPLY SIRONA news, Director Eric Brandt sold 6,900 shares of the company’s stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total transaction of $273,999.00. Following the sale, the director now owns 35,155 shares in the company, valued at $1,396,005.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.76% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in the stock. Cooke & Bieler LP boosted its holdings in shares of DENTSPLY SIRONA by 16.6% during the second quarter. Cooke & Bieler LP now owns 4,710,212 shares of the medical instruments supplier’s stock valued at $168,296,000 after acquiring an additional 669,035 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in DENTSPLY SIRONA by 11.0% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 7,609 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 753 shares during the last quarter. Empirical Asset Management LLC boosted its stake in DENTSPLY SIRONA by 131.1% during the 2nd quarter. Empirical Asset Management LLC now owns 10,609 shares of the medical instruments supplier’s stock valued at $379,000 after purchasing an additional 6,019 shares during the period. IFM Investors Pty Ltd grew its position in DENTSPLY SIRONA by 8.6% in the 2nd quarter. IFM Investors Pty Ltd now owns 37,709 shares of the medical instruments supplier’s stock worth $1,347,000 after purchasing an additional 2,972 shares during the last quarter. Finally, Raymond James Trust N.A. increased its stake in shares of DENTSPLY SIRONA by 52.5% in the second quarter. Raymond James Trust N.A. now owns 10,740 shares of the medical instruments supplier’s stock valued at $384,000 after purchasing an additional 3,698 shares during the period. 94.79% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Qualtrics International (NASDAQ:XM) PT Lowered to $16.00

Points.com (NASDAQ:PCOM) Now Covered by StockNews.com